Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2025-06-05 00:00:00 ET · period of report 2025-06-03 · accession 0001415889-25-015780 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-05 | 2025-06-03 | KNSA | Moat Ross | Chief COMMERCIAL Off | S - Sale+OE | $29.02 | -27.6K | 9,415 | -75% | -$800.8K |
| D | 2025-06-05 | 2025-06-03 | KNSA | Moat Ross | Chief COMMERCIAL Off | M - OptEx | $13.35 | +27.6K | 37.0K | +293% | +$368.4K |
| D | 2025-06-05 | 2025-06-03 | KNSA | Moat Ross | Chief COMMERCIAL Off | M - OptEx | $0.00 | -27.6K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Share | 2025-06-03 | S | D | 27,594 | $29.02 | 9,415 | D | — | — | (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $29.00 and $29.115. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
| 2 | Common | Class A Ordinary Share | 2025-06-03 | M | A | 27,594 | $13.35 | 37,009 | D | — | — | |
| 3 | Derivative | Share Option | 2025-06-03 | M | D | 27,594 | $0.00 | 0 | D | $13.35 · — to 2029-06-30 | 27,594 Class A Ordinary Share | (F3) The option is fully vested and exercisable. |